Galapagos NV (GXEA) - Total Liabilities
Based on the latest financial reports, Galapagos NV (GXEA) has total liabilities worth €119.06 Million EUR (≈ $139.19 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GXEA long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Galapagos NV - Total Liabilities Trend (2016–2025)
This chart illustrates how Galapagos NV's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Galapagos NV total assets.
Galapagos NV Competitors by Total Liabilities
The table below lists competitors of Galapagos NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Skywater Technology Inc
NASDAQ:SKYT
|
USA | $218.62 Million |
|
Akzo Nobel India Limited
NSE:AKZOINDIA
|
India | Rs13.44 Billion |
|
Aygaz AS
IS:AYGAZ
|
Turkey | TL12.66 Billion |
|
Lucid Group Inc
NASDAQ:LCID
|
USA | $5.45 Billion |
|
Shanghai Shyndec Pharmaceutical Co Ltd
SHG:600420
|
China | CN¥3.42 Billion |
|
Bros Eastern Co Ltd
SHG:601339
|
China | CN¥4.37 Billion |
|
HeBei Jinniu Chemical Industry Co Ltd
SHG:600722
|
China | CN¥102.39 Million |
|
Absci Corp
NASDAQ:ABSI
|
USA | $23.62 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Galapagos NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Galapagos NV to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galapagos NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galapagos NV (2016–2025)
The table below shows the annual total liabilities of Galapagos NV from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €170.65 Million ≈ $199.51 Million |
-86.22% |
| 2024-12-31 | €1.24 Billion ≈ $1.45 Billion |
-20.68% |
| 2023-12-31 | €1.56 Billion ≈ $1.83 Billion |
-29.28% |
| 2022-12-31 | €2.21 Billion ≈ $2.58 Billion |
-13.39% |
| 2021-12-31 | €2.55 Billion ≈ $2.98 Billion |
-16.33% |
| 2020-12-31 | €3.05 Billion ≈ $3.56 Billion |
-4.56% |
| 2019-12-31 | €3.19 Billion ≈ $3.73 Billion |
+1317.53% |
| 2018-12-31 | €225.25 Million ≈ $263.34 Million |
-17.88% |
| 2017-12-31 | €274.29 Million ≈ $320.68 Million |
-15.51% |
| 2016-12-31 | €324.64 Million ≈ $379.53 Million |
-- |
About Galapagos NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more